Advaxis publishes new results on Listeria-derived ActA anti-cancer component Advaxis.

Advaxis publishes new results on Listeria-derived ActA anti-cancer component Advaxis, Inc http://www.suhagrarx.com/ . Yvonne Paterson, at the University of Pennsylvania, it was discovered that ActA, either fused to an antigen and shipped with a live, attenuated Listeria vaccine or as a combination with an antigen rather than secreted by Listeria, led to a therapeutic immune response against TC-1 tumor cells. Moreover, it was found that the adjuvant actions of ActA stimulated immunity in the existence of immune tolerance, enabling a therapeutic response in animals whose immune systems were fatigued and ineffective against the prospective antigen.Gov. Source Advaxis, Inc.

Advaxis doses first individual in FDA-approved phase II CIN trial Advaxis, Inc., , the live, attenuated Listeria monocytogenes biotechnology company, has dosed the 1st patient in its US Meals and Medication Administration -approved, stage II medical trial in cervical intraepithelial neoplasia , commonly known as cervical dysplasia. The dosing was administered at the site of Dr. Keith Aqua, M.D. Of the Institute for Women’s Wellness & Body. Dosing the 1st patient is a substantial milestone for our firm, commented Advaxis Chairman/CEO Thomas A. Moore. It is a highly awaited advancement amongst all Advaxis and immunotherapy fans, at large; following a recent Dendreon Company FDA acceptance.